ERBB2 and breast cancer: The recent update of the ASCO practice guidelines recommends the use of multigene assays (MGAs) in adjuvant decision-making for HR+/HER2- early BC and highlights the optimal placement of tests in different patient settings, recognizing the 21-gene test (Oncotype DX) as one of the most widely used [1].